# Urokinase

## UROKINASE 60000IU

| 藥物代碼           | IUROK                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Acute coronary embolism, clearance of occluded catheters & shunts, acute pulmonary embolism, peripheral arterial or venous thromboembolism.                                                                                                                                                                                                                                                                                                       |
| 副作用             | Bleeding tendency. Fever, chills, headache & malaise may occur. Rarely, shock, sweating, disturbed pulse & dyspnea; rash, urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria.Hematologic: Decreased hematocrit level (37%)                                                                                                                                                                                            |
| 禁忌               | Intracranial hemorrhage, hemoptysis, difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.                                                                                                                                                                                                                                    |
| 藥物保存方式       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 用法用量           | Cerebral thrombosis (within 5 days after onset of symptoms & without hemorrhage) 60,000 iu once daily for 7 days. Peripheral arterial/venous occlusion 60,000 to 240,000 iu on first day of treatment followed by tapered doses for about 7 days. Acute coronary embolism 26,000-52,000 iu daily for 7 days. Deep vein thrombosis or acute pulmonary embolism IV loading 250,000 iu/hr, then 1,000 iu/kg/hr (or 60,000 -100,000 iu/hr) for 72 hr. |
| 肝功能異常         | 無需調整劑量  有嚴重肝腎障礙病人需謹慎使用。                                                                                                                                                                                                                                                                                                                                                                                                      |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 懷孕用藥危分級     | 可能安全                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                            |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期用藥建議     | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 注射劑給藥建議途徑 | IA, IPL, IRR, IVD                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 乾粉稀釋液         | 10 mL N/S,D5W                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 輸注點滴液         | 【D5W】 可選  【N/S】 可選                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IVD 用法建議       | 稀釋到總體積為195 mL,起始劑量:90 mL/hr 輸注超過 10 minutes,維持劑量:15 mL/hr 持續12小時                                                                                                                                                                                                                                                                                                                                                           |
| 注意事項           | 1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr                                                                                                                                                                                                                                                                                   |

